Home · Medications · Semaglutide
Single-receptor GLP-1 agonist (Ozempic, Wegovy, Rybelsus)

Semaglutide

Semaglutide is a single-receptor GLP-1 agonist developed by Novo Nordisk. Available as Ozempic® (T2D), Wegovy® (weight management), and Rybelsus® (oral T2D). STEP-1 demonstrated 14.9% weight loss at 2.4 mg weekly over 68 weeks.

Dr. Parmis - Medical Researcher
Researched By
Dr. Parmis
Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Adam Kennah, M.D.
Board-Certified Physician
Last clinically reviewed: April 28, 2026 · This page is informational and does not constitute medical advice.

About Semaglutide

Semaglutide is a single-receptor GLP-1 agonist developed by Novo Nordisk. Available as Ozempic® (T2D), Wegovy® (weight management), and Rybelsus® (oral T2D). STEP-1 demonstrated 14.9% weight loss at 2.4 mg weekly over 68 weeks.

Manufacturer / source: Novo Nordisk

How it compares

For tirzepatide forms head-to-head, see comparison page. For trial data, see clinical research.

Compounded medications: Compounded versions of these medications are not FDA-approved and are not the same as the brand-name products. Always discuss prescription decisions with a licensed clinician.
Editor's Pick

NexLife Tirzepatide

Compounded semaglutide + tirzepatide · MD/DO oversight

$186/month*

*12-month plan · flat rate · all titration doses

  • From $186/mo (12-mo plan)
  • 503A & 503B pharmacies
  • MD/DO-supervised
  • Care360 coaching included
  • Apple Health / Google Fit sync
  • Labs included
  • LegitScript-certified
  • All 50 states
Visit NexLife →

Or call (949) 818-8000